

APR 11 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

b7C

In re Application of )  
OUIMET et al. )  
Serial No. 09/647,780 ) Art Unit: 1645  
Filed: December 26, 2000 ) P06910US00/BAS  
For: NOVEL NEP II MEMBRANE )  
METALLOPROTEASE AND ITS USE )  
FOR SCREENING INHIBITORS )  
USEFUL IN THERAPY )

RECEIVED

APR 30 2002

TECH CENTER 1600/2900

LETTER - REQUEST FOR CORRECTED FILING RECEIPT

Assistant Commissioner of Patents

Washington, D.C. 20231

SIR:

Correction of the Filing Receipt is requested.

Submitted herewith is a copy of the Filing Receipt for the above-identified application showing the correction in red. The correction is readily apparent from the declaration.

Because this is the error of the Patent Office, no fee is enclosed herewith.

It is respectfully requested that the records of the Patent Office be corrected and that a corrected Filing Receipt be sent to the undersigned.

Respectfully submitted,

By:

B. Aaron Schulman  
Registration No. 31,877

Date: 11 April 2002

LARSON & TAYLOR PLC  
Transpotomac Plaza  
1199 North Fairfax Street, Suite 900  
Alexandria, Virginia 22314  
(703) 739-4900



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP/ART UNIT	FIL FEE REC'D	ATTY/DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/647,780	12/26/2000	1645	1120	P06910US00/BAS	14	14	2

881  
LARSON & TAYLOR, PLC  
1199 NORTH FAIRFAX STREET  
SUITE 900  
ALEXANDRIA, VA 22314

RECEIVED

APR 30 2002

TECH CENTER 1600/2900

CONFIRMATION NO. 3825  
CORRECTED FILING RECEIPT




\*OC000000007786085\*

Date Mailed: 04/03/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Tanja Ouimet, Paris, FRANCE;  
Claude Gros, Paris, FRANCE;  
Christiane Rose, St Denis, FRANCE;  
Marie-Chantal Bonhomme, St-Laurent, CANADA;  
Patricia Facchinetto, Les Plessis, FRANCE;  
Jean-Charles Schwartz, Paris, FRANCE;



**Domestic Priority data as claimed by applicant**

THIS APPLICATION IS A 371 OF PCT/FR99/00807 04/07/1999

**Foreign Applications**

FRANCE 98/04389 04/08/1998

**If Required, Foreign Filing License Granted 04/03/2002**

**Projected Publication Date:** Not Applicable, filed prior to November 29, 2000

**Non-Publication Request:** No

**Early Publication Request:** No

**Title**

Novel nep ii membrane metalloprotease and its use for screening inhibitors useful in therapy

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).